Restoring the dysfunctional endothelium

Current Pharmaceutical Design

Volumn 13, Issue 10, 2007, Pages 1053-1068

  Osto, Elena ^a   Coppolino, Giuseppe ^b   Volpe, Massimo ^c   Cosentino, Francesco ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

ACEI; ARB; Atherosclerosis; Coronary artery disease; Endothelial dysfunction; Nitric oxide; Review; Statin

Indexed keywords

ACETYLCHOLINE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ASCORBIC ACID; ATORVASTATIN; BOSENTAN; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR ANTAGONIST; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRBESARTAN; LOSARTAN; MEVINOLIN; NEBIVOLOL; NIPRADILOL; NITRIC OXIDE; OXYGEN RADICAL; PERINDOPRIL; PLACEBO; PRAVASTATIN; QUINAPRIL; RAMIPRIL; SIMVASTATIN; TELMISARTAN; TETRAHYDROBIOPTERIN; UNINDEXED DRUG; VALSARTAN;

ACUTE CORONARY SYNDROME; ANTIINFLAMMATORY ACTIVITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG MEGADOSE; ENDOTHELIAL DYSFUNCTION; HIGH RISK PATIENT; HUMAN; IMMUNOMODULATION; INFLAMMATION; MEDIATOR; MONOTHERAPY; MORTALITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOSIS; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR AGENTS; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE; RECEPTORS, ENDOTHELIN;

EID: 34247849412     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780487566     Document Type: Review

References (227)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle to acetylcholine. Nature 1980; 288: 373-6.
2. Cosentino F, Luscher TF. Maintenance of vascular integrity: Role of nitric oxide and other bradykinin mediators. Eur Heart J 1995; 16 (K): 4-12.
3. Kinlay S, Libby P, Ganz P. Endothelial function and coronary artery disease. Curr Opin Lipidol 2001; 12: 383-9.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 1993; 329: 2002-12.
5. Radomski MW, Palmer RM, Moncada S. The role of nitric oxide and cGMP in platelet adhesion to vacsular endothelium. Biochem Biophys Res Commun 1987; 148: 1482-9.
6. Sarkar R, Meinberg EG, Stanley JC, Gordon D, Webb RC. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996; 78: 225-30.
7. Kubes P, Suzuki M, Granger DN. Nitric oxide: An endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991; 88: 4651-5.
8. Zeiher AM, Fisslthaler B, Schray-Utz B, Busse R. Nitric oxide modulates the expression of monocyte chemoattractant protein 1 in cultured human endothelial cells. Circ Res 1995; 76: 980-6.
9. Libby P. Changing concepts of atherogenesis. J Intern Med 2000; 247: 349-58.
10. Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000; 121: 437-43.
11. Mohamed AK, Bierhaus A, Schiekofer S, Tritschler H, Ziegler R, Nawroth PP. The role of oxidative stress and NF-kappaB activation in late diabetic complications. Biofactors 1999; 10: 157-67.
12. Collins T, Cybulsky MI. NF-kappa B: Pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107: 255-64.
13. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003; 23: 168-75
14. Beckam JS, Koppenol WH. Nitric oxide, superoxide and peroxynitrite: The good, the bad and the ugly. Am J Physiol 1996; 271: C1424-37.
15. Weyrich AS, MA XL, Buerke M, Murohara T, Amstead Ve, Lefer AM, et al. Physiological concentrations of nitric oxide do not elicit an acute negative inotropic effect in unstimulated cardiac muscle. Circ Res 1994; 75: 692-700.
16. Miles AM, Bohle DS, Glassbrennor PA, Hansert B, Wink DA, Grisham MB. Modulation of superoxide-dependent oxidation and hydroxylation reactions by nitric oxide. J Biol Chem 1996; 271: 40-7.
17. Liu S, Beckam JS, Ku DD. Peroxynitrite, a product of superoxide and nitric oxide, produces coronary vasorelaxation in dogs. J Pharmacol Exp Ther 1994; 268: 1114-21.
18. Ku DD, Liu S, Dai J. Coronary vascular and antipplatelet effects of peroxynitrite in human tissues. Endothelium 1995; 3: 309-19.
19. Wu MN, Pritchard KA, Kaminski PM, Fayngersh RP, Hintze TH, Wolin MS. Involvment of nitric oxide and nitrosothiols in relaxation of pulmonary arteries to peroxynitrite. Am J Physiol 1994; 266: H2108-13.
20. Moro MA, Darley-Usmar VM, Goodwin DA, Read NG, Zamora-Pinto R, Feelisch M, et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA 1994; 91: 6702-6.
21. Lefer DJ, Scalia R, Campbell B, Nossuli T, Hayward R, Salamon M, et al. Peroxynitrite inhibits leukocyte-endothelial cell interactions and progress against ischemia-reperfusion injury in rats. J Clin Invest 1997; 99: 684-91.
22. Moro MA, Darley-Usmar VM, Lizasoain I, Su Y, Knowles RG, Radomski MW, et al. The formation of nitric oxide donors from peroxynitrite. Br J Pharmacol 1995; 116: 1999-2004.
23. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: A product from the reaction of nitric oxide and superoxide. Am J Physiol 1995; 268: L699-722.
24. Beckam JS, Beckam TW, Chen J, Marshall PA, Freeman BA. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc Natl Acad Sci USA 1990; 87: 1620-4.
25. Ischiropoulos H, Al-Mehdi AB. Peroxynitrite-mediated oxidative protein modifications. FEBS Lett 1995; 364: 279-82.
26. White CR, Darley-Usmar V, Berrington WR, McAdams M, Gore JZ, Thompson JA, et al. Circulating plasma xanthine oxidase contributes to vascular dysfunction in hypercholesterolemic rabbits. Proc Natl Acad Sci USA 1996; 93: 8745-9.
27. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest 1993; 91: 2546-51.
28. Buttery LD, Springall DR, Chester AH, Evans TJ, Stanfield EN, Parums DV, et al. Inducible nitric oxide synthase is present within human atherosclerotic lesions and promotes the formation and activity of peroxynitrite. Lab Invest 1996; 75: 77-85
29. Ma XL, Lopez BL, Liu GL, Christopher TA, Gao F, Guo YP, et al. Hypercholesterolemia impairs a detoxification mechanism against peroxynitrite and renders the vascular tissue more susceptible to oxidative injury. Circ Res 1997; 80: 894-901.
30. Leewenburgh C, Hardy MM, Hazen SL, Wagner P, Ohishi S, Steinbrecher UP, et al. Reactive nitrogen intermediates promote low density lipoprotein oxidation in human atherosclerotic intima. J Biol Chem 1997; 272: 1433-6.
31. Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol 1996; 7: 274-80.
32. Laskey RE, Mathews WR. Nitric oxide inhibits peroxynitrite-induced production of hydroxyeicosatetraenoic acids and F2-isoprostanes in phosphatidylcholine liposomes. Arch Biocherm Biophys 1996; 330: 193-8.
33. Forman HJ, Fukuto JM, Torres M. Redox signaling: Thiol chemistry defines which reactive oxygen and nitrogen species can act as second messangers. Am J Physiol Cell Physiol 2004; 287: C246-56.
34. Cai H, Harrison. Endothelial Dysfunction in cardiovascular diseases. The role of oxideant stress. Circ Res 2000; 87: 840-4.
35. Rabelink TJ, Luscher TF. Endothelial Nitric Oxide Synthase. Host defense enzyme of the endothelium? Arterioscler Thromb Vasc Biol 2006; 26: 267-71.
36. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986; 315: 1046-51.
37. Quyyumi AA, Dakak N, Andrews NP, Husain S, Arora S, Gilligan DM, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest 1995; 95: 1747-55.
38. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-5.
39. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995; 91: 1314-9
40. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfield JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-74.
41. Corretti MC, Plotnick GD, Vogel RA. Correlation of cold pressor and flow-mediated brachial artery diameter responses with the presence of coronary artery disease. Am J Cardiol 1995; 75: 783-7.
42. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995; 26: 1235-41.
43. Takase B, Uehata A, Akima T, Nagai T, Nishioka T, Hamabe A, et al. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am J Cardiol 1998; 82: 1535-9.
44. Takase B, Hamabe A, Satomura K, Akima T, Uehata A, Matsui T, et al. Comparable prognostic value of vasodilator response to acetylcholine in brachial and coronary arteries for predicting long-term cardiovascular events in suspected coronary artery disease. Circ J 2006; 70: 49-56.
45. Wu WC, Sharma SC, Choudhary G, Coulter L, Coccio E, Eaton CB. Flow-mediated vasodilation predicts the presence and extent of coronary artery disease assessed by stress thallium imaging. J Nucl Cardiol 2005; 12: 538-44.
46. Eskurza I, Seals DR, DeSouza CA, Tanaka H. Pharmacologic versus flow-mediated assessments of peripheral vascular endothelial vasodilatory function in humans. Am J Cardiol 2001; 88: 1067-9.
47. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127: 2254-63.
48. Alam TA, Seifalian AM, Baker D. A review of methods currently used for assessment of in vivo endothelial function. Eur J Vasc Endovasc Surg 2005; 29: 269-76.
49. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948-54.
50. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101: 1899-1906.
51. Halcox JP, Schenke WH, Zalos G, Mincemoyer R, Prasad A, Waclawiw MA, et al. Prognostic value of coronary vascular endothelial function. Circulation 2002; 106: 653-8.
52. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104: 191-6.
53. Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T. Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001; 104: 2673-8.
54. Gotlieb AI. Atherosclerosis and acute coronary syndromes. Cardiovasc Pathol 2005; 14: 181-4.
55. Aikawa M, Libby P. The vulnerable atherosclerotic plaque: Pathogenesis and therapeutic approach. Cardiovasc Pathol 2004; 13: 125-38.
56. Napoli C, De Nigris F, Palinski W. Multiple role of reactive oxygen species in the arterial wall. J Cell Biochem 2001; 82: 674-82.
57. Kurose I, Kubes P, Wolf R, Anderson DC, Paulson J, Miyasaka M, et al. Inhibition of nitric oxide production. Mechanisms of vascular albumin leakage. Circ Res 1993; 73: 164-71.
58. Felton CV, Crook D, Davies MJ, Oliver MF. Relation of plaque lipid composition and morphology to the stability of human aortic plaques. Arterioscler Thromb Vasc Biol 1997; 17: 1337-45
59. Colangelo S, Langille BL, Steiner G, Gotlieb AI. Alterations in endothelial F-actin microfilaments in rabbit aorta in hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 52-6.
60. Farb A, Burke AP, Tang AL, Liang TY, Mannan P, Smialek J, et al. Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death. Circulation 1996; 93: 1354-63.
61. Rajavashisth TB, Liao JK, Galis ZS, Tripathi S, Laufs U, Tripathi J, et al. Inflammatory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane type 1-matrix metalloproteinase. J Biol Chem 1999; 274: 11924-9
62. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. Blood 1997; 89: 2429-42
63. Sata M, Walsh K. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-9
64. Tricot O, Mallat Z, Heymes C, Belmin J, Leseche G, Tedgui A. Relation between endothelial cell apoptosis and blood flow direction in human atherosclerotic plagues. Circulation 2000; 101: 2450-3.
65. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-60.
66. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001; 89: E1- 7.
67. Schmidt-Lucke C, Rossig L, Fichtlscherer S, Vasa M, Britten M, Kamper U, et al. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: Proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005; 111: 2981-7
68. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque: A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-7.
69. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, et al. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-25.
70. Kwon H, Sangiorgi G, Ritman E, McKenna C, Holmes DJ, Schwartz R, et al. Enhanced coronary vasa vasorum neovascolarization in experimental hypercholesterolemia. J Clin Invest 1998; 101: 1551-6.
71. Wilson S, Herrmann J, Lerman L, Holmes DJ, Napoli C, Ritman ER, Lerman A. Simvastatin preserves the structure of coronary adventitial vasa vasorum in experimental hypercholesterolemia independent of lipid lowering. Circulation 2002; 105: 415-8.
72. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, et al. Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol 2005; 25: 2054-61
73. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E, et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003; 100: 4736-41.
74. Steffel J, Luscher TF, Tanner FC. Tissue factor in cardiovascular diseases: Molecular mechanisms and clinical implications. Circulation 2006; 113: 722-31
75. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-9.
76. Sheperd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, NcFarlane PW, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7.
77. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-9.
78. LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
79. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of Cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
80. Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HA, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebocontrolled trial. Lancet 2004; 364: 685-96.
81. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronaAy syndromes: The MIRACL study: a randomised controlled trial. JAMA 2001; 285: 1711-8.
82. Aronow HD, Topol EJ, Roe MT, Houghtaling PL, Wolski KE, Lincoff AM, et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-8.
83. Stenesrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430-6.
84. Nissen SE, Tuzcu EM, Schoenhagen P, Brown BG, Ganz P, Vogel RA, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004; 291: 1071-80.
85. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352: 29-38
86. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504
87. Vaughan CJ, Gotto AM Jr., Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35: 1-10.
88. Ray KK, Cannon CP. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005; 46: 1425-33.
89. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997; 95: 76-82.
90. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterollowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496-500.
91. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-31.
92. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolaemia. Circulation 1994; 89: 2519-24.
93. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995; 332: 481-7.
94. Tan KC, Chow WS, Tam SC, Ai VH, Lam CH, Lam KS. Atorvastatin lowers C-reactive protein and improves endotheliumdependent vasodilation in Type 2 diabetes mellitus. J Clin Endocrinol Metab 2002; 87: 563-8.
95. Dupuis J, Tardif JC, Cernacek P, Theroux P. Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (Reduction of Cholesterol in Ischemia and Function of the Endothelium) trial. Circulation. 1999; 99: 3227-33.
96. Chin J.H., Azhar S, Hoffman BB. Inactivation of endothelial- derived relaxing factor by oxidized lipoproteins. J Clin Invest 1992; 89: 10-18.
97. Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004; 110: 1933-9.
98. Gorlach A, Brandes RP, Nguyen K, Amidi M, Deghani F, Busse R. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res 2000; 87: 26-32.
99. Wassmann S, Laufs U, Baümer AT, Müller K, Konkol C, Sauer H, et al. Inhibition of geranylgeranylation reduces angiotensin II-mediated free radical production in vascular smooth muscle cells: Involvement of angiotensin AT1 receptor expression and Rac1 GTPAse. Mol Pharmacol 2001; 59: 646-54.
100. Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20: 61-9.
101. Laufs U, La Fata V, Plutzky J, Liao JK. Up-regulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97: 1129-35.
102. Laufs U, Liao JK. Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 1998; 273: 24266-71.
103. Eto M, Barandier C, Rathgeb L, Kozai T, Joch H, Yang Z, et al. Thrombin suppresses endothelial nitric oxide synthase and upregulates endothelin-converting enzyme-1 expression by distinct pathways: Role of Rho/ROCK and mitogen-activated protein kinase. Circ Res 2001; 89: 583-90.
104. Takemoto M, Sun J, Hiroki J, Shimokawa H, Liao JK. Rho-kinase mediates hypoxia-induced down-regulation of endothelial nitric oxide synthase. Circulation 2002; 106: 57-62.
105. Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 1999; 399: 597-601.
106. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, Zeiher AM. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 1999; 399: 601-5.
107. Eto M, Kozai T, Cosentino F, Joch H, Luscher TF. Statin prevents tissue factor expression in human endothelial cells: Role of Rho/Rho-kinase and Akt pathways. Circulation 2002; 105: 1756-9.
108. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001; 104: 365-72.
109. Libby P, Aikawa M. Mechanisms of plaque stabilization with statins. Am J Cardiol. 2003; 91: 4B-8B.
110. Rosemberg RD, Aird WC. Vascular bed specific hemostasis and hypercogulable states. N Engl J Med 1999; 340: 1555-64.
111. Kaikita K, Takeya M, Ogawa H, Suefuji H, Yasue H, Takahashi K. Co-localization of tissue factor and tissue factor pathway inhibitor in coronary atherosclerosis. J Pathol 1999; 188: 180-8.
112. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature 2000; 407: 258-64.
113. Laufs U, Liao JK. Targeting Rho in cardiovascular disease. Circ Res 2000; 87: 526-8.
114. Davidson MH, Stein EA, Dujovne CA, Hunninghake DB, Weiss SR, Knopp RH, et al. The efficacy and six-week tolerability of simvastatin of 80 and 160 mg/day. Am J Cardiol 1997; 79: 38-42.
115. Aznar J, Estelles A. Role of plasminogen activator inhibitor type 1 in the pathogenesis of coronary artery diseases. Haemostasis 1994; 24: 243-51.
116. Wiman B. Plasminogen activator inhibitor type 1 in plasma: Its role in thrombotic disease. Thromb Haemostasis 1995; 74: 71-6.
117. Hamsten A, de Faire U, Walldius G, Dahlen G, Szamosi A, Landou C, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
118. Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA 1992; 89: 6998-7002.
119. Nagata K, Ishibashi T, Sakamoto T, Nakazato K, Seino Y, Yokoyama K, et al. Effects of blockade of the renin angiotensin system on tissue factor and plasminogen activator inhibitor synthesis in human cultured monocytes. J Hypertens 2001; 19: 775-83.
120. Kooistra T, Schrauwen Y, Arts J, Emeis JJ. Regulation of endothelial cells t-PA synthesis and release. Int J Hematol 1994; 59: 233-55.
121. Essig M, Nguyen G, Prie D, Escoubet B, Sraer JD, Friedlander G. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins. Circ Res 1998; 83: 683-90.
122. Lopez S, Peiretti F, Bonardo B, Juhan-Vague I, Nalbone G. Effect of atorvastatin and fluvastatin on the expression of plasminogen activator inhibitor type 1 in cultured human endothelial cells. Atherosclerosis 2000; 152: 359-66.
123. White HD. Should all patients with coronary disease receive angiotensin-converting-enzyme? Lancet 2003; 362: 755-6.
124. Richard V, Joannides R, Henry JP, Mulder P, Mace B, Guez D, et al. Fixed-dose combination of perindopril with indapamide in spontaneously hypertensive rats: Haemodynamic, biological and structural effects. J Hypertens 1996; 14: 1447-54.
125. Hayakawa H, Cofee K, Raij L. Endothelial dysfunction and cardiorenal injury in experimental salt-sensitive hypertension: Effects of antihypertensive therapy. Circulation 1997; 96: 2407-13.
126. Napoli C, Sica V, de Nigris F, Pignalosa O, Condorelli M, Ignarro LJ, et al. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J 2004; 148: E5.
127. Taddei S, Virdis A, Ghiadoni L, Mattei P, Salvetti A. Effects of angiotensin converting enzyme inhibition on endothelium-dependent vasodilatation in essential hypertensive patients. J Hypertens 1998; 16: 447-56.
128. Bayorh MA, Ganafa AA, Eatman D, Walton M, Feuerstein GZ. Simvastatin and losartan enhance nitric oxide and reduce oxidative stress in salt-induced hypertension. Am J Hypertens 2005; 18: 1496-502.
129. de Gasparo M, Hess P, Nuesslein-Hildesheim B, Bruneval P, Clozel JP. Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J Renin Angiotensin Aldosterone Syst 2000; 1: 151-8.
130. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101: 1653-9.
131. Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension 2000; 35: 501-6.
132. Klingbeil AU, John S, Schneider MP, Jacobi J, Handrock R, Schmieder RE. Effect of AT1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16: 123-8.
133. Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S, et al. Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension 2003; 41: 1281-6.
134. Hornig B, Landmesser U, Kohler C, Ahlersmann D, Spiekermann S, Christoph A, et al. Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: Role of superoxide dismutase. Circulation 2001; 103: 799-805.
135. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertension 1994; 12S9: S17-22.
136. Dzau VJ. Tissue angiotensin and pathobiology of vascular disease. A unifying hypothesis. Hypertension 2001; 37: 1047-52.
137. Brown NJ, Vaughn DE. Prothrombotic effects of angiotensin. Adv Intern Med 2000; 45: 419-29.
138. Gryglewski RJ. Pharmacology of vascular endothelium. Delivered on 27 June 2004 at the 29th FEBS Congress in Warsaw. FEBS J 2005; 272: 2956-67.
139. Zafari AM, Ushio-Fukai M, Akers M, Yin Q, Shah A, Harrison DG, et al. Role of NADH/NADPH oxidase-derived H2O2 in angiotensin II-induced vascular hypertrophy. Hypertension 1998; 32: 488-95.
140. Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A Paradigm shift? Circulation 1994; 89: 493-8.
141. Wu L, Iwai M, Nagakami H, Li Z, Chen R, Suzuki J, et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation 2001; 104: 2716-21.
142. Mancini GB, Henry GC, Macaya C, O' Neill BJ, Pucillo AL, Carere RG, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing EN-dothelial Dysfunction) Study. Circulation 1996; 94: 258-65.
143. Asselbergs FW, van der Harst P., Jessurun GAJ, Tio RA, van Gilst WH. Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vasc Pharmacol 2005; 42: 125-40.
144. Anderson TJ, Elstein E, Haber H, Charbonneau F. Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow mediated dilation in patients with coronary artery disease (BANFF study). J Am Coll Cardiol 2000; 35: 60-6.
145. Prasad A, Halcox JP, Waclawiw MA, Quyyumi AA. Angiotensin type 1 receptor antagonism reverses abnormal coronary vasomotion in atherosclerosis. J Am Coll Cardiol 2001; 38: 1089-95.
146. Prasad A, Tupas-Habib T, Schenke WH, Mincemoyer R, Panza JA, Waclawin MA, et al. Acute and chronic angiotensin-1 receptor antagonism reverses endothelial dysfunction in atherosclerosis. Circulation 2000; 101: 2349-54.
147. Hornig B, Kohler C, Drexler H. Role of bradykinin in mediating vascular effects of ACE-inhibitors in humans. Circulation 1997; 95: 1115-8.
148. Benzing T, Fleming I, Blaukat A, Muller-Esterl W, Busse R. Angiotensin converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. Circulation 1999; 99: 2034-40.
149. Gohlke P, Pees C, Unger T. AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. Hypertension 1998; 31: 349-55.
150. Tsutsumi Y, Matsubara H, Kurihara H, Murosawa S, Takai S, Miyazaki M. Angiotensin II type 2 overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest 1999; 104: 925-35.
151. Campbell DJ, Krum H, Esler MD. Losartan increases bradykinin levels in hypertensive humans. Circulation 2005; 111: 315-20.
152. Heart Outcomes Prevention Evaluation Study Investigators. Effects of angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 145-53.
153. EUROPA Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362: 782-8.
154. The Scientific Committee of the PERTINENT Sub-study on behalf of the EUROPA-PERTINENT Investigators. PERTINENT-PERindopril-Thrombosis, Inflammation, Endothelial dysfunction and Neurohumoral activation Trial. Cardiovasc Drug Ther 2003; 17: 83-91.
155. Navalkar S, Parthasarathy S, Santanam N, Khan BV. Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis. J Am Coll Cardiol 2001; 37: 440-4.
156. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-906.
157. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
158. Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: The CHARM-Overall programme. Lancet 2003; 362: 759-66.
159. Liang C, Wu ZG, Ding J, Jiang JF, Huang GZ, Du RZ, et al. Losartan inhibited expression of matrix metalloproteinases in rat atherosclerotic lesions and angiotensin II-stimulated macrophages. Acta Pharmacol Sin 2004; 25: 1426-32.
160. Nickenig G. Should Angiotensin II Receptor Blockers and Statins Be Combined? Circulation 2004; 110: 1013-20
161. Zimmermann M, Unger T. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme. Expert Opin Pharmacother 2004; 5: 1201-8.
162. Held PH, Yusuf S. Effects of beta-blockers and calcium channel blockers in acute myocardial infarction. Eur Heart J 1993; 14: 18-25.
163. 1-adrenoceptor antagonist, nebivolol. Cardiov Drug Rev 2004; 22: 155-68.
164. Andre DE, Arnet U, Yang Z, Lüscher TF. Nebivolol inhibits human aortic smooth muscle cell growth: Effects on cell cycle regulatory proteins. J Cardiovasc Pharmacol 2000; 35: 845-8.
165. Brehm BR, Wolf SC, Bertsch D, Klaussner M, Wesselborg S, Schuler S, et al. Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. Cardiovasc Res 2001; 49: 430-9.
166. Ignarro LJ, Byrns RE, Trinh K, Sisodia M, Buga GM. Nebivolol: A selective beta1- adrenergic receptor antagonist that relaxes vascular smooth muscle by nitric oxide and cyclic GMP-dependent mechanisms. Nitric Oxide 2002; 7: 75-82.
167. Cockcroft JR, Chowienczyk PJ, Brett SE, Chen CP, Dupont AG, Van Nueten L, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71.
168. Bowman AJ, Chen CP, Ford GA. Nitric oxide mediated venodilator effects of nebivolol. Br J Clin Pharmacol 1994; 38: 199-204.
169. Gao YS, Nagao T, Bond RA, Janssens WJ, Vanhoutte PM. Nebivolol induces endothelium-dependent relaxations of canine coronary arteries. J Cardiovasc Pharmacol 1991; 17: 964-9.
170. Parenti A, Filippi S, Amerini S, Granger HJ, Fazzini A, Ledda F. Inositol phosphate metabolism and nitric-oxide synthase activity in endothelial cells are involved inthe vasorelaxant activity of nebivolol. J Pharmacol Exp Ther 2000; 292: 698-703.
171. Kubli S, Feihl F, Waeber B. Beta-blockade with nebivolol enhances the acetylcholine-induced cutaneous vasodilation. Clin Pharmacol Ther 2001; 69: 238-44.
172. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: A randomized, doublebind, crossover study. Circulation 2001; 104: 511-4.
173. Janssen PM, Zeitz O, Hasenfuss G. Transient and sustained impacts of hydroxyl radicals on sarcoplasmic reticulum function: Protective effects of nebivolol. Eur J Pharmacol 1999; 366: 223-32.
174. Mollnau H, Schulz E, Daiber A, Baldus S, Oelze M, August M, et al. Nebivolol prevents vascular NOSIII uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells. Arterioscler Thromb Vasc Biol 2003; 23: 615-21.
175. Fratta Pasini A, Garbin U, Nava MC, Stranieri C, Davoli A, Sawamura, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and increases nitric oxide by reducing its oxidative activation. J Hypertens 2005; 23: 589-96.
176. Hayashi T, Iguchi A. Nipradilol: A β-adrenoceptor antagonist with nitric oxide releasing action. Cardiov Drug Rev 1998; 16: 212-35.
177. Igarashi M, Hirata A, Yamaguchi H, Sugae N, Kadomoto Y, Jimbu Y, et al. Mechanism of an inhibitory effect of nipradilol on rat vascular smooth muscle growth. J Atheroscler Thromb 2003; 10: 226-33.
178. Thakur NK, Hayashi T, Sumi D, Kano H, Matsui-Hirai H. Tsunekawa T, et al. Anti-atherosclerotic effect of β-blocker with nitric oxide-releasing action on the severe atherosclerosis. J Cardiovasc Pharmacol 2002; 39: 298-309.
179. Boulanger CM, Tanner FC, Bea ML, Hahn AW, Werner A, Luscher TF. Oxidized low density lipoproteins induce mRNA expression and release of endothelin from human and porcine endothelium. Circ Res 1992; 70: 1191-7.
180. Luscher TF, Oemar BS, Boulanger CM, Hahn AW. Molecular and cellular biology of endothelin and its receptors-Part II. J Hypertens 1993; 11: 121-6.
181. Kowala MC, Rose PM, Stein PD, Goller N, Recce R, Beyer S, et al. Selective blockade of the endothelin subtype A receptor decreases early atherosclerosis in hamsters fed cholesterol. Am J Pathol 1995; 146: 819-26.
182. Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Luscher TF. Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1998; 95: 14367-72.
183. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC Jr. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-1001.
184. Zeiher AM, Goebel H, Schachinger V, Ihling C. Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. Circulation 1995; 91: 941-7.
185. Zeiher AM, Ihling C, Pistorius K, Schachinger V, Schaefer HE. Increased tissue endothelin immunoreactivity in atherosclerotic lesions associated with acute coronary syndromes. Lancet 1994; 344: 1405-6.
186. Omland T, Lie RT, Aakvaag A, Aarsland T, Dickstein K. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 1994; 89: 1573-9.
187. Wenzel RR, Fleisch M, Shaw S, Noll G, Kaufmann U, Schmitt R, et al. Hemodynamic and coronary effects of the endothelin antagonist bosentan in patients with coronary artery disease. Circulation 1998; 98: 2235-40.
188. Kyriakides ZS, Kremastinos DT, Psychari SN, Kolettis T, Sbarouni E, Webb DJ. Coronary vasoconstriction after coronary angioplasty is attenuated by endothelin a receptor antagonism. Am J Cardiol 2001; 87: 1011-3; A5.
189. Bohm F, Beltran E, Pernow J. Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition. J Intern Med 2005; 257: 263-71.
190. Schiffrin EL, Sventek P, Li JS, Turgeon A, Reudelhuber T. Antihypertensive effect of an endothelin receptor antagonist in DOCA-salt spontaneously hypertensive rats. Br J Pharmacol 1995; 115: 1377-81.
191. Stasch JP, Hirth-Dietrich C, Frobel K, Wegner M. Prolonged endothelin blockade prevents hypertension and cardiac hypertrophy in stroke-prone spontaneously hypertensive rats. Am J Hypertens 1995; 8: 1128-34.
192. Dhaun N, Strachan FE, Newby DE, Johnston NR, Ford NF, Hammett JL, et al. Vasodilator effects of the endothelin ET receptor selective antagonist BMS-193884 in healthy men. Br J Clin Pharmacol 2005; 60: 611-22.
193. Haynes WG, Ferro CJ, O'Kane KP, Somerville D, Lomax CC, Webb DJ. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 1996; 93: 1860-70.
194. Haynes WG, Webb DJ. Contribution of endogenous generation of endothelin-1 to basal vascular tone. Lancet 1994; 344: 852-4.
195. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998; 338: 784-90.
196. Stroes E, Kastelein J, Cosentino F, Erkelens W, Wever R, Koomans H, et al. Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J Clin Invest 1997; 99: 41-6.
197. Chen PY, Sanders PW. Role of nitric oxide synthesis in salt-sensitive hypertension in Dahl/Rapp rats. Hypertension 1993; 22: 812-8.
198. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest 1992; 90: 1168-72.
199. Vasquez-Vivar J, Kalyanaraman B, Martasek P, Hogg N, Masters BS, Karoui H, et al. Superoxide generation by endothelial nitric oxide synthase: The influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220-5.
200. Pou S, Pou WS, Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified brain nitric oxide synthase. J Biol Chem 1992; 267: 24173-6.
201. Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial nitric oxide synthase in hypertension: Role of the NAD(P)H oxidase. J Clin Invest 2003; 111: 1201-9.
202. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999; 43: 274-8.
203. Katusic ZS. Vascular endothelial dysfunction: Does tetrahydrobiopterin play a role? Am J Physiol Heart Circ Physiol 2001; 281: H981-6.
204. - imbalance in insulin-resistant rat aorta. Diabetes 1999; 48: 2437-45.
205. Laursen JB, Somers M, Kurz S, McCann L, Warnholtz A, Freeman BA, et al. Endothelial regulation of vasomotion in apoE-deficient mice: implications for interactions between peroxynitrite and tetrahydrobiopterin. Circulation 2001; 103: 1282-8.
206. Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 1435-8.
207. Cosentino F, Patton S, d'Uscio LV, Werner ER, Werner-Felmayer G, Moreau P, et al. Tetrahydrobiopterin alters superoxide and nitric oxide release in prehypertensive rats. J Clin Invest 1998; 101: 1530-7.
208. Setoguchi S, Mohri M, Shimokawa H, Takeshita A. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 2001; 38: 493-8.
209. Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol 2000; 35: 173-8.
210. Loscalzo J. L-arginine and atherothrombosis. J Nutr 2004; 134: 2798S-800S.
211. Gornig HL, Creager MA. Arginine and endothelial and vascular health. J Nutr 2004; 134: 2880S-7S.
212. Herman AG, Moncada S. Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis. Eur Heart J 2005; 26: 1945-55.
213. Böger RH, Ron ES. L-arginine improves vascular function by overcoming the deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005; 10(1): 14-23.
214. Walker HA, Mc Ging E, Fisher I, Boger RH, Bode-Boger SM, Jackson G, et al. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: Lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. J Am Coll Cardiol 2001; 38: 499-505.
215. Loscalzo J. Adverse effects of supplemental L-arginine in atherosclerosis. Consequences of methylation stress in a complex catabolism? Arterioscler Thromb Vasc Biol 2003; 22: 3-5.
216. Sominet S, Rupin A, Badier-Commander C, Coumailleau S, Behr-Roussel D, Verbeuren TJ. Evidence for superoxide anion generation in aortas of cholesterol-fed rabbits treated with L-arginine. Eur J Pharmacol 2004; 492: 211-6.
217. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost. 2005; 3: 1646-54.
218. Woo KS, Chook P, Lolin YI, Sanderson JE, Metreweli C, Celermajer DS. Folic acid improves arterial endothelial function in adults with hyperhomocystinemia. J Am Coll Cardiol 1999; 34: 2002-6.
219. Bellamy MF, McDowell IF, Ramsey MW, Brownlee M, Newcombe RG, Lewis MJ. Oral folate enhances endothelial function in hyperhomocysteinaemic subjects. Eur J Clin Invest 1999; 29: 659-62.
220. Verhaar MC, Wever RM, Kastelein JJ, van Dam T, Koomans HA, Rabelink TJ. 5-methyltetrahydrofolate, the active form of folic acid, restores endothelial function in familial hypercholesterolemia. Circulation 1998; 97: 237-41.
221. Stroes ES, van Faassen EE, Yo M, Martasek P, Boer P, Govers R. Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res 2000; 86: 1129-34.
222. Tawakol A, Migrino RQ, Aziz KS, Waitkowska J, Holmvang G, Alpert, et al. NMHigh-dose folic acid acutely improves coronary vasodilator function in patients with coronary artery disease. J Am Coll Cardiol 2005; 45: 1580-4.
223. Title LM, Cummings PM, Giddens K, Genest JJ Jr, Nassar BA. Effect of folic acid and antioxidant vitamins on endothelial dysfunction in patients with coronary artery disease. J Am Coll Cardiol 2000; 36: 758-65.
224. Clarke R. Homocysteine-lowering trials for prevention of heart disease and stroke. Semin Vasc Med 2005; 5: 215-22.
225. Bivalacqua TJ, Musicki B, Usta MF, Champion HC, Kadowitz PJ, Burnett AL, et al. Endothelial nitric oxide synthase gene therapy for erectile dysfunction. Curr Pharm Des 2005; 11(31): 4059-67.
226. Burnett AL, Musicki B. The nitric oxide signaling pathway in the penis. Curr Pharm Des 2005; 11(31): 3987-94.
227. Dinh T, Veves A. Microcirculation of the diabetic foot. Curr Pharm Des 2005; 11(18): 2301-9.